Truist Lowers its Price Target on Insulet Corporation (PODD) to $360 and Maintains a Buy Rating
Truist on February 19, 2026, lowered its price target on Insulet Corporation (NASDAQ:PODD) to $360 from $390 and maintained a Buy rating.
Insulet Corp (PODD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 459,115 | $130,498,891 | +162% | 0.07% |
| 2. | GLG Partners Noam Gottesman | 434,568 | $123,521,608 | -6% | 0.21% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 324,717 | $92,297,563 | +16% | 0.08% |
| 4. | Renaissance Technologies Jim Simons | 303,283 | $86,205,160 | -23% | 0.13% |
| 5. | Millennium Management Israel Englander | 232,949 | $66,213,424 | +16% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $246.23 | 2,030 | $499,846.90 | 17,483 | 2026-02-25 | Filing | |
| $239.35 | 4,300 | $1,029,205.00 | 13,916 | 2026-02-20 | Filing | |
| $311.73 | 962 | $299,884.26 | 4,591 | 2025-12-05 | Filing | |
| $206.00 | 100 | $20,600.00 | 13,314 | 2024-08-29 | Filing | |
| $168.92 | 1 | $168.92 | 4,032 | 2023-09-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $293.09 | 1,851 | $542,509.59 | 2,158 | 2025-12-15 | Filing | |
| $347.49 | 687 | $238,725.63 | 3,456 | 2025-09-08 | Filing | |
| $348.81 | 797 | $278,001.57 | 3,890 | 2025-09-08 | Filing | |
| $332.23 | 4,263 | $1,416,296.49 | 16,736 | 2025-08-21 | Filing | |
| $320.00 | 1,343 | $429,760.00 | 4,143 | 2025-08-07 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,701,472 | $2,473,306,401 | 0.04% | |
| 2. | 6,578,887 | $1,869,982,939 | 0.03% | |
| 3. | 6,325,354 | $1,797,918,592 | 0.09% | |
| 4. | 4,408,972 | $1,253,223,507 | 0.23% | |
| 5. | 3,155,489 | $896,916,193 | 0.03% |
News See All
O5 Adoption Leads to Bullish Views Around Insulet Corporation (PODD)
On February 4, Stifel lowered its price target on Insulet Corporation (NASDAQ:PODD) from $370 to $350. The firm reiterated a Buy rating on the shares, with a revised upside of almost 45%.
10 Best Healthcare Equipment Stocks to Buy According to Hedge Funds
The Healthcare Equipment segment is one of the areas across the broader healthcare landscape that carries immense innovation prospects and also offers a defensive play.
Insulet Corporation (NASDAQ:PODD) Q4 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Insulet Corporation Fourth Quarter and Full Year 2025 Earnings Call. As a reminder, this conference call is being recorded.
Insulet Corporation (PODD) Announces Strategic Expansion and Supply Agreement Update
Insulet Corporation (NASDAQ:PODD) is one of the best medical technology stocks to invest in.
10 Best Medical Technology Stocks to Invest In
Medical technology, or MedTech, companies ensure that the broader healthcare industry has the tools needed to diagnose, treat, monitor, or prevent medical conditions.
Insulet Corporation (PODD): A Bull Case Theory
We came across a bullish thesis on Insulet Corporation on The Wealth Dynasty Report’s Substack. In this article, we will summarize the bulls’ thesis on PODD.
Reasons Why Hedge Funds Favor Insulet Corp (PODD)
As of the close of play on January 28, Insulet Corporation (NASDAQ:PODD) carried a highly bullish consensus view.
12 Best Medical Devices Stocks to Invest In According to Hedge Funds
It is challenging to identify segments within the markets that appear to be defensive plays, yet offer innovation potential.
Bernstein Reduces Firm’s PT on Insulet (PODD) Stock
Insulet Corporation (NASDAQ:PODD) is one of the Best Fundamental Stocks to Buy According to Analysts.
Hedge Fund Resource Center